Floatz logo

Topamax

Mood Disorders

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Mood Disorders cohort.

Asset / SponsorPhaseRating
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BBB
Arestin
Pakistan Institute of Living and Learning
Phase 4BBB
Olanzapine
University of Ghana Medical School
Phase 4BBB
FLUOXETINE
University of Ghana Medical School
Phase 4BBB

View all 36 →

Same molecule, other indications

Topamax is also rated in:

focal epilepsyDormant
A
Indicative ·
80 / 100
View asset →
migraine without auraDormant
BBB
Indicative ·
78 / 100
View asset →
migraine with auraDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →